Purchase this article with an account.
Rafael A. Bueno-Garcia, Janet Monrroy-Herrera; Intravitreal Ranibizumab Injection Combined With Laser Photocoagulation In Proliferative Diabetic Retinopathy With Macular Edema. Invest. Ophthalmol. Vis. Sci. 2012;53(14):3288.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate therapeutic effects and usefulness of treatment of intravitreal injection of Anti-VGF (Lucentis 0.5 mg) after panretinal photocoagulation (PRP) in patients with clinically significant macular edema secondary to proliferative diabetic retinopathy (PDR).
We review the charts of 59 patients (66 eyes) with macular edema and PDR with full PRP who were treated with Lucentis 0.5mg between October 2010 and October 2011. We analyzed best-corrected visual acuity (BCVA), fluorescein angiography, and OCT.
All patient received full PRP at least 1 moth before star Anti-VGF therapy. The total injections was 239. The average injection performed to treat DME was 3.5; BCVA (log MAR) improved from preoperative 0.87±0.36 to 0.83±0.46 at 3 months and it was maintained until at least 2 months. No one patient required additional laser PRP during the studied period. The thickness of fovea decreased from average 306.08±73.57 µm to average 250.0±57.92 µm at 3 months, which was significantly maintained during 2 months.
Therapy with Intravitral Ranibizumab after PRP might be an effective treatment modality in the treatment of macular edema and PDR, and might prevent the subsequent PRP need in PDR patients, Intravitreal Ranibizumab might be effective for reducing diabetic macular edema and preventing aggravation of PDR with stabilization of the vision
This PDF is available to Subscribers Only